XOMA Royalty Revenue Soars 131% on Strong Royalty Performance

TL;DR

**XOMAP is a buy; their royalty portfolio is firing on all cylinders, driving massive revenue and net income growth.**

AI Summary

XOMA Royalty Corp (XOMAP) reported a significant increase in total income and revenues for the six months ended June 30, 2025, reaching $29.041 million, up from $12.576 million in the prior-year period. This 130.9% surge was primarily driven by a substantial increase in income from purchased receivables under the cost recovery method, which jumped from $870,000 to $7.268 million, and under the EIR method, rising from $4.562 million to $12.077 million. Net income for the six-month period also saw a healthy increase to $11.558 million in 2025, compared to $7.390 million in 2024. Operating expenses decreased by 37.6% to $18.509 million, largely due to the absence of the $9.000 million credit losses on purchased receivables recorded in 2024. The company's cash and cash equivalents decreased from $101.654 million at December 31, 2024, to $75.060 million at June 30, 2025. Strategic activities included the acquisition of BioInvent's remaining rights to milestone payments and royalties in May 2025 and the acquisition of LAVA Therapeutics N.V. in August 2025, indicating an active portfolio expansion strategy. The company also saw a decrease in long-term debt from $106.875 million to $102.201 million.

Why It Matters

XOMA Royalty Corp's robust revenue growth, driven by its royalty and commercial payment portfolio, signals strong underlying performance in its acquired assets, which is crucial for a company focused on intellectual property monetization. For investors, this indicates effective portfolio management and potentially higher future returns, especially with the reduction in long-term debt. Employees benefit from a more stable and growing company, while customers (the licensees) are seeing their products generate significant revenue, validating their development efforts. In the competitive landscape of biotech royalty companies, XOMA's ability to significantly increase income from purchased receivables positions it favorably, demonstrating its capacity to identify and acquire valuable income streams.

Risk Assessment

Risk Level: medium — While XOMA Royalty Corp shows strong revenue growth, its cash and cash equivalents decreased by $26.594 million from December 31, 2024, to June 30, 2025, indicating significant cash usage. The company also has substantial long-term debt of $102.201 million, which, despite a slight reduction, still represents a significant financial obligation. The nature of royalty income can be volatile, dependent on the success of third-party products, as evidenced by the $9.000 million credit losses on purchased receivables in the prior year, though absent this period.

Analyst Insight

Investors should consider XOMA Royalty Corp (XOMAP) as a potential investment, given its impressive 130.9% revenue growth and improved net income. Monitor future cash flow statements closely to ensure the company's cash burn is sustainable and that new acquisitions continue to generate strong returns, further reducing reliance on debt.

Financial Highlights

debt To Equity

0.99

revenue

$29.041M

operating Margin

-63.6%

total Assets

$223.456M

total Debt

$113.873M

net Income

$11.558M

eps

$0.96

gross Margin

N/A

cash Position

$75.060M

revenue Growth

+130.9%

Revenue Breakdown

Key Numbers

• $29.041M — Total income and revenues (Increased by 130.9% from $12.576 million for the six months ended June 30, 2024)
• $11.558M — Net income (Increased from $7.390 million for the six months ended June 30, 2024)
• $7.268M — Income from purchased receivables under cost recovery method (Increased from $870,000 for the six months ended June 30, 2024)
• $12.077M — Income from purchased receivables under EIR method (Increased from $4.562 million for the six months ended June 30, 2024)
• $18.509M — Total operating expenses (Decreased by 37.6% from $29.659 million for the six months ended June 30, 2024)
• $75.060M — Cash and cash equivalents (Decreased from $101.654 million at December 31, 2024)
• $102.201M — Long-term debt (Decreased from $106.875 million at December 31, 2024)
• $9.000M — Credit losses on purchased receivables (Absent in the six months ended June 30, 2025, compared to the prior year)
• $45.434M — Intangible assets, net (Increased from $25.909 million at December 31, 2024, reflecting new acquisitions)
• 12,087,719 — Shares of common stock outstanding (As of August 8, 2025)

Key Players & Entities

• XOMA Royalty Corporation (company) — Registrant in the 10-Q filing
• BioInvent International AB (company) — Company from which XOMA acquired remaining rights to milestone payments and royalties in May 2025
• LAVA Therapeutics N.V. (company) — Company acquired by XOMA in August 2025
• Alexion Pharmaceuticals (company) — Party in an Exclusive License Agreement with XOMA dated December 19, 2024
• Blue Owl Capital Corporation (company) — Lender in the Blue Owl Loan Agreement dated December 15, 2023
• Kinnate Biopharma Inc. (company) — Company acquired by XOMA, resulting in a gain on acquisition in 2024
• Takeda Pharmaceutical Company Limited (company) — Partner in a Collaboration Agreement with XOMA dated November 1, 2006
• Organon International GmbH (company) — Licensee of XACIATO from Dar Bioscience, Inc.
• Janssen Biotech, Inc. (company) — Party in a License Agreement with XOMA dated August 5, 2019
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for the 10-Q filing

FAQ

Risk Factors

• Credit Risk on Receivables [high — financial]: The company's revenue is significantly dependent on royalty and commercial payments from third parties. A substantial increase in income from purchased receivables under both the cost recovery and EIR methods highlights this dependence. Deterioration in the financial health of these third parties could lead to defaults and negatively impact XOMA's cash flows and profitability.
• Integration of Acquisitions [medium — operational]: XOMA has actively expanded its portfolio through acquisitions, including BioInvent's remaining rights and LAVA Therapeutics N.V. The successful integration of these acquired assets and businesses is critical. Failure to achieve expected synergies or operational efficiencies from these acquisitions could hinder growth and dilute shareholder value.
• Valuation of Intangible Assets [medium — market]: Intangible assets, net, increased significantly from $25.909 million to $45.434 million, reflecting new acquisitions. The valuation of these intangible assets is subject to significant judgment and estimation. Changes in market conditions or the performance of underlying assets could lead to impairment charges, impacting the company's financial statements.
• Evolving Healthcare Landscape [medium — regulatory]: As a royalty company focused on the healthcare sector, XOMA is exposed to the risks associated with drug development, regulatory approvals, and market adoption of new therapies. Changes in healthcare policies, reimbursement rates, or the success of partnered products can directly affect royalty income.
• Liquidity and Cash Position [medium — financial]: Cash and cash equivalents decreased from $101.654 million to $75.060 million. While still substantial, this reduction, coupled with ongoing strategic acquisitions and debt obligations, necessitates careful cash flow management to ensure sufficient liquidity for operations and future investments.
• Debt Management [medium — financial]: The company has long-term debt totaling $102.201 million. While this has decreased from $106.875 million, the servicing of this debt requires consistent cash flow. Any disruption to revenue generation could strain the company's ability to meet its debt obligations.

Industry Context

XOMA operates in the specialized royalty and life sciences sector, acquiring rights to future payments from pharmaceutical and biotechnology products. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success hinges on identifying promising assets and effectively managing a diverse portfolio of royalty streams, often through strategic acquisitions and partnerships.

Regulatory Implications

As a company whose revenue is tied to pharmaceutical products, XOMA is indirectly affected by FDA approvals, pricing regulations, and patent expirations. Changes in healthcare policy or the regulatory status of partnered drugs can materially impact royalty income. Compliance with financial reporting standards, particularly for revenue recognition on complex royalty agreements, is also critical.

What Investors Should Do

1. Monitor the performance of newly acquired assets (BioInvent rights, LAVA Therapeutics)
2. Analyze the sustainability of revenue growth from purchased receivables
3. Evaluate the company's cash flow management and liquidity
4. Assess the impact of intangible asset valuations

Key Dates

• 2025-05-01: Acquisition of BioInvent's remaining rights to milestone payments and royalties — Expands XOMA's royalty portfolio and potential future revenue streams.
• 2025-08-01: Acquisition of LAVA Therapeutics N.V. — Further diversifies and strengthens XOMA's asset base, indicating an active growth strategy.
• 2025-06-30: XOMA Royalty Corp Q2 2025 Earnings Release — Reported significant revenue and net income growth, driven by royalty income and reduced operating expenses.
• 2024-12-31: End of Fiscal Year 2024 — Reported $101.654 million in cash and cash equivalents and $106.875 million in long-term debt.

Glossary

EIR method

Effective Interest Rate method, used for recognizing income from royalty and commercial payment receivables, reflecting the time value of money. (Key method for recognizing a significant portion of XOMA's revenue, impacting reported income and asset values.)

Cost recovery method

A method of accounting where revenue is recognized only when the costs incurred are recovered, often used for receivables where collectability is uncertain. (Another primary method for recognizing income from receivables, contributing significantly to the reported revenue increase.)

Intangible assets, net

Non-physical assets that have value, such as patents, copyrights, and goodwill, acquired through business combinations or other means. 'Net' indicates accumulated amortization and impairment. (Increased substantially due to acquisitions, representing a significant portion of the company's assets and subject to valuation risks.)

Credit losses on purchased receivables

Losses recognized when a borrower or counterparty fails to make payments on a receivable that the company has purchased. (The absence of these losses in the current period significantly improved operating expenses and net income compared to the prior year.)

RPAs, AAAs, and CPPAs

These likely refer to types of agreements such as Royalty Purchase Agreements, Asset Acquisition Agreements, and Collaboration and Partnership Agreements, which can involve contingent consideration. (Contingent consideration related to these agreements decreased, impacting current liabilities.)

Exarafenib milestone asset

An asset representing potential future milestone payments related to the drug Exarafenib, which is subject to contingent consideration. (This asset and its associated contingent consideration are tracked separately, indicating specific strategic partnerships.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, XOMA Royalty Corp. reported a dramatic 130.9% increase in total income and revenues to $29.041 million, a significant improvement from $12.576 million in the prior year. This surge was primarily fueled by substantial growth in income from purchased receivables under both the cost recovery and EIR methods. Net income also saw a healthy rise to $11.558 million from $7.390 million. Operating expenses decreased by 37.6% to $18.509 million, largely due to the absence of $9.000 million in credit losses on purchased receivables recorded in the prior year, which significantly boosted profitability.

Key Financial Figures

• $0.0075 — ge on which registered: Common Stock, $0.0075 par value XOMA The Nasdaq Global Ma
• $0.05 — ve Perpetual Preferred Stock, par value $0.05 XOMAP The Nasdaq Global Market De

Filing Documents

• xoma-20250630x10q.htm (10-Q) — 3144KB
• xoma-20250630xex3d2.htm (EX-3.2) — 75KB
• xoma-20250630xex3d3.htm (EX-3.3) — 92KB
• xoma-20250630xex3d4.htm (EX-3.4) — 86KB
• xoma-20250630xex10d2.htm (EX-10.2) — 69KB
• xoma-20250630xex31d1.htm (EX-31.1) — 14KB
• xoma-20250630xex31d2.htm (EX-31.2) — 14KB
• xoma-20250630xex32d1.htm (EX-32.1) — 8KB
• 0001558370-25-011305.txt ( ) — 15011KB
• xoma-20250630.xsd (EX-101.SCH) — 109KB
• xoma-20250630_cal.xml (EX-101.CAL) — 92KB
• xoma-20250630_def.xml (EX-101.DEF) — 534KB
• xoma-20250630_lab.xml (EX-101.LAB) — 825KB
• xoma-20250630_pre.xml (EX-101.PRE) — 756KB
• xoma-20250630x10q_htm.xml (XML) — 2819KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 50 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 59 Item 4.

Controls and Procedures

Controls and Procedures 59 PART II OTHER INFORMATION 61 Item 1.

Legal Proceedings

Legal Proceedings 61 Item 1A.

Risk Factors

Risk Factors 61 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 61 Item 3. Defaults Upon Senior Securities 62 Item 4. Mine Safety Disclosures 62 Item 5. Other Information 62 Item 6. Exhibits 63

Signatures

Signatures 65 2 Table of Contents GLOSSARY OF TERMS AND ABBREVIATIONS Abbreviations Definition 2010 Plan The Company's 2010 Long Term Incentive and Stock Award Plan, as amended 2018 Common Stock ATM Agreement At The Market Issuance Sales Agreement with HCW dated December 18, 2018 2021 Series B Preferred Stock ATM Agreement At The Market Issuance Sales Agreement with B. Riley dated August 5, 2021 AAA Assignment and Assumption Agreement Affitech Affitech Research AS Affitech CPPA The Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021 Aptevo Aptevo Therapeutics Inc. Aptevo CPPA The Company's Payment Interest Purchase Agreement with Aptevo dated March 29, 2023, referred to herein as "Aptevo Commercial Payment Purchase Agreement" or "Aptevo CPPA" Alexion Alexion Pharmaceuticals Alexion License Agreement Exclusive License Agreement between the Company and Alexion (formerly Amolyt Pharma SAS, "Amolyt") dated December 19, 2024 ASC Accounting Standards Codification ASC 250 ASC Topic 250, Accounting Changes and Error Corrections ASC 310 ASC Topic 310, Receivables ASC 450 ASC Topic 450, Contingencies ASC 606 ASC Topic 606, Revenue from Contracts with Customers ASC 805 ASC Topic 805, Business Combinations ASC 815 ASC Topic 815, Derivatives and Hedging ASC 835-30 ASC Subtopic 835-30, Interest – Imputation of Interest ASC 842 ASC Topic 842, Leases ASU Accounting Standards Update Bayer License Agreement Out-license agreement to Bayer HealthCare LLC from Dar dated January 10, 2020, related to the development and commercialization of OVAPRENE BioInvent BioInvent International AB BioInvent License Agreement Cross-Licensing Agreement between the Company and BioInvent dated November 21, 2003, as amended on September 14, 2004, November 13, 2009, and September 6, 2018 BioInvent Agreement Royalty Purchase Agreement between Meza Royalty 1 LLC (a wholly-owned subsidiary of the Company) and BioInvent

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS XOMA ROYALTY CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in thousands, except share and per share amounts) June 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 75,060 $ 101,654 Short-term restricted cash 80 1,330 Investment in equity securities 8,801 3,529 Trade and other receivables, net 1,817 1,839 Short-term royalty and commercial payment receivables under the EIR method 17,960 14,763 Short-term royalty and commercial payment receivables under the cost recovery method 700 413 Prepaid expenses and other current assets 507 2,076 Total current assets 104,925 125,604 Long-term restricted cash 3,345 3,432 Property and equipment, net 26 32 Operating lease right-of-use assets 288 319 Long-term royalty and commercial payment receivables under the EIR method 4,775 4,970 Long-term royalty and commercial payment receivables under the cost recovery method 58,937 55,936 Exarafenib milestone asset 3,402 3,214 Investment in warrants 609 — Intangible assets, net 45,434 25,909 Other assets - long term 1,715 1,861 Total assets $ 223,456 $ 221,277 LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,138 $ 1,053 Accrued and other liabilities 5,411 5,752 Contingent consideration under RPAs, AAAs, and CPPAs — 3,000 Operating lease liabilities 472 446 Unearned revenue recognized under units-of-revenue method 1,434 1,361 Preferred stock dividend accrual 1,368 1,368 Current portion of long-term debt 11,672 11,394 Total current liabilities 21,495 24,374 Unearned revenue recognized under units-of-revenue method – long-term 3,666 4,410 Exarafenib milestone contingent consideration (Note 4) 3,402 3,214 Long-term operating lease liabilitie

View Full Filing

View this 10-Q filing on SEC EDGAR